Literature DB >> 21403667

Hematology: Rituximab for follicular lymphoma: maintaining an open mind.

Bruce D Cheson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21403667     DOI： 10.1038/nrclinonc.2011.35

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Authors:  Roswitha Forstpointner; Michael Unterhalt; Martin Dreyling; Hans-Peter Böck; Roland Repp; Hannes Wandt; Christiane Pott; John F Seymour; Bernd Metzner; Annette Hänel; Tanja Lehmann; Frank Hartmann; Hermann Einsele; Wolfgang Hiddemann
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

2.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Authors:  Marinus H J van Oers; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars Van't Veer; Andrej Vranovsky; Harald Holte; Martine van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

3.  Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Authors:  Marinus H J van Oers; Martine Van Glabbeke; Livia Giurgea; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Mars van t Veer; Andrej Vranovsky; Harald Holte; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

4.  Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.

Authors:  John D Hainsworth; Sharlene Litchy; Don W Shaffer; Van L Lackey; Manuel Grimaldi; F Anthony Greco
Journal:  J Clin Oncol       Date:  2005-01-18       Impact factor: 44.544

5.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321

6.  Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.

Authors:  H Hagberg; C Gisselbrecht
Journal:  Ann Oncol       Date:  2006-05       Impact factor: 32.976

7.  Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.

Authors:  Giovanni Martinelli; Shu-Fang Hsu Schmitz; Urs Utiger; Thomas Cerny; Urs Hess; Simona Bassi; Emmie Okkinga; Roger Stupp; Rolf Stahel; Marc Heizmann; Daniel Vorobiof; Andreas Lohri; Pierre-Yves Dietrich; Emanuele Zucca; Michele Ghielmini
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

8.  Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

Authors:  Howard Hochster; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J Horning
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
  8 in total
  1 in total

Review 1.  Trial Watch: Immunostimulatory cytokines.

Authors:  Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-05-07       Impact factor: 8.110
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.